Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Granisetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 12/20 | 0.98 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.98 |
| ▸ | HTR3B | O95264 | 1/20 | 0.98 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.98 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.98 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.98 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.98 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.89 |
| ▸ | TSHR | P16473 | 1/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Granisetron SCHEMBL34177 | 1.00 | HTR3A (0.98) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL33433 | 1.00 | HTR3A (0.98) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL30773918 | 1.00 | HTR3A (0.98) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL5067161 | 0.99 | HTR3A (0.96) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL445223 | 0.99 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL16642163 | 0.99 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL13660190 | 0.99 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL4890 | 0.99 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL4109977 | 0.99 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL34178 | 0.99 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3821 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| US-20250222003-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-07-10 | — | — | US | claimed |
| CN-119868293-A | Granisetron slow release medicine for relieving chemotherapy or postoperative vomiting | 郑州大学第一附属医院 | 2025-04-25 | — | — | CN | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| WO-2004111192-A2 | TARGETED DELIVERY TO LEGUMAIN-EXPRESSING CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-12-23 | — | — | WO | claimed |
| US-20040248960-A1 | Process for preparing 1-methylindazole-3-carboxylic acid | CHEMAGIS LTD. (IL) | 2004-12-09 | — | — | US | claimed |
| EP-1484321-A1 | Process for preparing 1-methylindazole-3-carboxylic acid | Chemagis Ltd. (IL) | 2004-12-08 | — | — | EP | claimed |
| US-20040202651-A1 | Uses of anti-insulin-like growth factor 1 receptor antibodies | PFIZER INC. | 2004-10-14 | — | — | US | claimed |
| WO-2004012699-A2 | MODIFIED RELEASE COMPOSITION COMPRISING COATED MICRO MATRIX PARTICLES CONTAINING THE HIGH SOLUBLE ACTIVE INGREDIENT AND A RELEASE CONTROLLING AGENT | TORRENT PHARMACEUTICALS LIMITED (IN) | 2004-02-12 | — | — | WO | claimed |
| US-6589941-B1 | Preventing or reducing formation of resistance in cytostatic treatment comprising combining BVDU, a salt thereof or BVDU in protected form or in prodrug form with at least one cytostatic agent in order to prevent or reduce the formation | RESPROTECT GMBH (DE) | 2003-07-08 | — | — | US | claimed |
| WO-2003013482-A1 | TRANSDERMAL DELIVERY OF 5-HT3 ANTAGONISTS | STRAKAN GROUP LIMITED (GB) | 2003-02-20 | — | — | WO | claimed |
| US-6440453-B1 | MIXTURE WITH TEA TREE OIL, ETHANOL AND WATER; SIDE EFFECT REDUCTION DURING CHEMOTHERAPY FOR CANCER AND/OR TUMORS | NOVOSIS PHARMA AG (DE) | 2002-08-27 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5756514-A | Methods for treatment and prevention of drug-induced pruritus with serotonin type 3 receptor antagonists | LARIJANI GHASSEM E (US) | 1998-05-26 | — | — | US | claimed |